title: Influence of Chemotherapy on the Antioxidant Status of Human Skin.
abstract: BACKGROUND
  Palmoplantar erythrodysesthesia is a frequent dermal side-effect during chemotherapy. Previous investigations showed radical formation subsequent to doxorubicin infusion and preventative and therapeutic effects of an antioxidant-containing ointment.
  
  
  METHODS
  Using a non-invasive vivomeasuring system (Biozoom®; Biozoom Services GmbH, Kassel, Germany) changes in the antioxidant status (as measured by relative carotenoid concentration) of the skin prior to and after intravenous administration of paclitaxel, docetaxel and 5-fluorouracil were investigated in 42 patients with cancer.
  
  
  RESULTS
  A significant decrease of antioxidant concentration subsequent to intravenous administration was found for all investigated chemotherapeutic agents. The mean concentration of carotenoids decreased from 3.59±1.26 arbitrary units (a.u.) to 3.41±1.28 a.u. (p<0.001) after paclitaxel administration, from 6.33±2.43 to 5.63±2.29 a.u. after docetaxel (p=0.027) and from 4.26±1.81 to 3.98±1.53 a.u. (p=0.042) after 5-fluorouracil infusion.
  
  
  CONCLUSIONS
  Oxidative stress might play a significant role in the pathomechanism of palmoplantar erythrodysesthesia associated with paclitaxel, docetaxel and 5-fluorouracil. Therefore, an antioxidant-containing ointment might serve as preventative and therapeutic option.
authors.affiliation: Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charité - University of Medicine Berlin, Berlin, Germany.
authors.forename: Bich Na
authors.initials: BN
authors.lastname: Lee
authors.affiliation: Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charité - University of Medicine Berlin, Berlin, Germany.
authors.forename: Sora
authors.initials: S
authors.lastname: Jung
authors.affiliation: Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charité - University of Medicine Berlin, Berlin, Germany.
authors.forename: Maxim E
authors.initials: ME
authors.lastname: Darvin
authors.affiliation: Department of Hematology and Oncology, Charité - University of Medicine Berlin, Berlin, Germany.
authors.forename: Jan
authors.initials: J
authors.lastname: Eucker
authors.affiliation: Department of Hematology and Oncology, Charité - University of Medicine Berlin, Berlin, Germany.
authors.forename: Dagmar
authors.initials: D
authors.lastname: Kühnhardt
authors.affiliation: Department of Gynecology, Charité - University of Medicine Berlin, Berlin, Germany.
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.affiliation: Department of Gynecology, Charité - University of Medicine Berlin, Berlin, Germany.
authors.forename: Radoslav
authors.initials: R
authors.lastname: Chekerov
authors.affiliation: Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charité - University of Medicine Berlin, Berlin, Germany.
authors.forename: Alexa
authors.initials: A
authors.lastname: Patzelt
authors.affiliation: Department of Hematology, Oncology and Palliative Care, Helios Hospital, Bad Saarow, Germany.
authors.forename: Harald
authors.initials: H
authors.lastname: Fuss
authors.affiliation: Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charité - University of Medicine Berlin, Berlin, Germany.
authors.forename: Ruo-Xi
authors.initials: RX
authors.lastname: Yu
authors.affiliation: Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charité - University of Medicine Berlin, Berlin, Germany.
authors.forename: Jürgen
authors.initials: J
authors.lastname: Lademann
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000975:Antioxidants / Q000378:metabolism*; D002338:Carotenoids / Q000378:metabolism*; D000077143:Docetaxel; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D060831:Hand-Foot Syndrome / Q000209:etiology / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use; D012867:Skin / Q000378:metabolism*; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D043823:Taxoids; D000077143:Docetaxel; D002338:Carotenoids; D004317:Doxorubicin; D017239:Paclitaxel; D005472:Fluorouracil
keywords: Hand–foot syndrome; antioxidants; dermal toxicity; palmar plantar erythrodysesthesia